Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)

Theravance Biopharma (TBPH) has disclosed Cash from Discontinued Operations for 1 consecutive years, with 178968000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Cash from Discontinued Operations changed N/A to 178968000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was 184566000.0, a N/A change, with the full-year FY2022 number at 184566000.0, down 761.12% from a year prior.
  • Cash from Discontinued Operations was 178968000.0 for Q4 2022 at Theravance Biopharma, down from 5209000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 615000.0 in Q1 2022 to a low of 178968000.0 in Q4 2022.